Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size (2024 - 2029)

The market size for acute respiratory distress syndrome treatment is projected to experience significant growth over the forecast period, driven by an increase in the prevalence of acute lung injury and a rise in COVID-19 cases leading to ARDS. Factors such as lifestyle-related diseases, air pollution, and accidents contributing to ARDS, along with a growing geriatric population, are expected to further expand the market. Additionally, increased healthcare spending and strategic initiatives by market participants present opportunities for growth. However, the high costs of treatment and regulatory challenges may pose constraints on the market's expansion.

Market Size of Global Acute Respiratory Distress Syndrome (ARDS) Treatment Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
ARDS Treatment Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 3.26 Billion
Market Size (2029) USD 4.30 Billion
CAGR (2024 - 2029) 5.65 %
Fastest Growing Market North America
Largest Market Asia-Pacific

Major Players

ARDS Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Acute Respiratory Distress Syndrome Treatment Market Analysis

The Global Acute Respiratory Distress Syndrome Treatment Market size is estimated at USD 3.26 billion in 2024, and is expected to reach USD 4.30 billion by 2029, growing at a CAGR of 5.65% during the forecast period (2024-2029).

According to the clinical data of COVID-19 patients with severe infection, radiologic evidence of lung edema shows that symptoms of Acute Lung Injury (ALI) can progress to hypoxemia and possibly ARDS in COVID-19 patients. According to the study titled "Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management" published in the Pneumonia in December 2021, about one-third or (33%) of hospitalized patients experience ARDS. Additionally, ARDS is present in almost 3/4 (or 75%) of COVID-19 patients admitted to the intensive care unit. ARDS patients with COVID-19 have a poor prognosis and a high mortality rate. Thus, the acute respiratory distress market has been significantly impacted by COVID-19.

The market for acute respiratory distress syndrome (ARDS) is being driven by factors such as the rising prevalence and incidence of acute lung injury, a wide range of ARDS risk factors, and an increase in the number of patients with COVID-19 who have ARDS. The global market for acute respiratory distress syndrome (ARDS) is also expected to grow as a result of factors such as the prevalence of diseases linked to lifestyle choices, air pollution, and accidents that cause ARDS. According to the study titled "Acute respiratory distress syndrome: Epidemiology, pathophysiology, pathology, and etiology in adults" by Mark D Siegel published in June 2022, around 190,000 ARDS cases are reported annually in the United States. The incidence rose with patient age, rising from 16 per 100,000 person-years for those aged 15 to 19 to 306 per 100,000 person-years for those aged 75 to 84. Moreover, the growing geriatric population supports market growth. For instance, as per United Nations Department of Economic and Social Affairs report titled 'World Population Ageing 2020 Highlights' mentioned that there were 727 million persons aged 65 years or over in the world in 2020. It is expected that the population is more than double and reaches nearly 1.5 billion in 2050. Since the older population is at high risk of getting respiratory and other illnesses, it is expected to generate the need for treatment, thereby driving the market's growth.

Furthermore, increasing healthcare spending and market participants' strategic initiatives present a growth opportunity for the global acute respiratory distress syndrome (ARDS) market. For Instance, In June 2020, NeuroRx, in partnership with Relief Therapeutics, announced that the United States Food and Drug Administration awarded Fast Track designation to NeuroRx for the investigation of RLF-100 (Aviptadil) for the treatment of acute lung injury/acute respiratory distress syndrome associated with COVID-19. Additionally, in November 2020, Novartis declared that it had entered into an exclusive worldwide license and collaboration agreement with Mesoblast to develop, market, and manufacture remestemcel-L to treat acute respiratory distress syndrome.

Thus, all aforementioned factors are expected to boost the market growth over the forecast period, However, high costs associated with the treatment and devices and regulatory complication may restraint the market growth.

Acute Respiratory Distress Syndrome Treatment Industry Segmentation

Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The main complication in ARDS is that fluid leaks into the lungs, making breathing difficult or impossible. The causes of ARDS are divided into two categories: direct or indirect injuries to the lung. Some of the direct injuries to the lung include pneumonia, aspiration, trauma, and others whereas the indirect injuries to the lung include inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions. Acute Respiratory Distress Syndrome (ARDS) Treatment Market is Segmented by Treatment (Drug Class, Devices), End User (Hospitals/Clinics, Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally.The report offers the value (in USD million) for the above segments.

By Treatment
By Drug Class
Vasoconstrictor
Bronchodilators
Streoid and Antibiotics
Sedative and Paralytic
Surfactant
Other
Devices
By End User
Hospitals/Clinics
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Summary

The global acute respiratory distress syndrome (ARDS) treatment market is poised for significant growth, driven by the increasing prevalence of acute lung injuries and the rising incidence of ARDS, particularly among COVID-19 patients. The market is influenced by various factors, including lifestyle-related diseases, air pollution, and accidents, which contribute to the development of ARDS. The aging population, which is more susceptible to respiratory illnesses, further supports market expansion. The market is also experiencing a boost from strategic initiatives by key players and increased healthcare spending, with companies like NeuroRx and Novartis making notable advancements in treatment options. Despite the high costs and regulatory challenges associated with ARDS treatments, the market is expected to grow steadily over the forecast period.

North America leads the global ARDS treatment market, supported by a robust healthcare system, a high prevalence of the condition, and the presence of major market players. The region benefits from frequent product approvals and a competitive landscape where companies are actively engaging in new product launches, partnerships, and collaborations. The market's growth is further bolstered by the increasing number of hospital admissions and critical care unit admissions, which create a heightened demand for ARDS treatments. Key players such as Faron Pharmaceuticals, BioMarck Pharmaceuticals, and GE Healthcare are maintaining substantial market shares through innovative strategies. As the market continues to evolve, it is expected to witness healthy growth, driven by the factors mentioned above.

Explore More

Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Prevalence of Acute Respiratory Distress Syndrome.

      2. 1.2.2 High Prevalence of Tobacco Smoking, Urbanization, And Growing Levels of Pollution

      3. 1.2.3 Growing Geriatric Population

    3. 1.3 Market Restraints

      1. 1.3.1 Unfavorable Reimbursement Scenario

      2. 1.3.2 Complications Associated with Treatments and High Cost of Devices and Treatments

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD Million)

    1. 2.1 By Treatment

      1. 2.1.1 By Drug Class

        1. 2.1.1.1 Vasoconstrictor

        2. 2.1.1.2 Bronchodilators

        3. 2.1.1.3 Streoid and Antibiotics

        4. 2.1.1.4 Sedative and Paralytic

        5. 2.1.1.5 Surfactant

        6. 2.1.1.6 Other

      2. 2.1.2 Devices

    2. 2.2 By End User

      1. 2.2.1 Hospitals/Clinics

      2. 2.2.2 Other End Users

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size FAQs

The Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market size is expected to reach USD 3.26 billion in 2024 and grow at a CAGR of 5.65% to reach USD 4.30 billion by 2029.

In 2024, the Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market size is expected to reach USD 3.26 billion.

Acute Respiratory Distress Syndrome Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)